Citations

Clear

6274 citation(s) found for "To, Andrew".

Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation
Shafi, Tariq , Zhu, Xiaoqian , Lirette, Seth T. , Rule, Andrew D. , Butler, Kenneth R. , Hall, Michael E. , Vaitla, Pradeep , Wynn, J. D. , Tio, Maria Clarissa , Butler, Javed , Butler, Kenneth R , Vaitla, Pradeep K , Wynn, James J , Guallar, Eliseo , Rule, Andrew D , Lirette, Seth , Shafi, Tariq , Mosley, Thomas H. , Dossabhoy, Neville R. , Güallar, Eliseo

Mayo Clinic

Annals of Internal Medicine | July 4, 2022 | Volume: 175 | Issue: 8 | Pages: 1073-1082

10.7326/m22-0610 | PMID 35785532 Get It

SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes
Pawlowski, Colin , Silvert, Eli , O’Horo, John C. , Lenehan, Patrick J. , Gnass, Esteban , Ross, Jason , Speicher, Leigh L. , Geyer, Holly L. , Venkatakrishnan, A J, Challener, Douglas , Ross, Jason , Speicher, Leigh, Geyer, Holly, Soundararajan, Venky , O'Horo, John C , Lenehan, Patrick J , Challener, Douglas W. , Murugadoss, Karthik , Venkatakrishnan, A J , Badley, Andrew D. , Soundararajan, Venky

Mayo Clinic

PNAS Nexus | July 4, 2022 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgac071 | PMID 35860600 Get It

Abstract Case reports of patients infected with COVID-19 and influenza virus (“flurona”) have raised questions around the prevalence and severity of coinfection. Using data from HHS Protect Public Data Hub, NCBI Virus, and CDC FluView, we analyzed trends in SARS-CoV-2 and influenza hospitalized coinfection cases and strain prevalences. We also characterized coinfection cases across the Mayo Clinic Enterprise from January 2020 to April 2022. We compared expected and observed coinfection case counts across different waves of the pandemic and assessed symptoms and outcomes of coinfection and COVID-19 monoinfection cases after propensity score matching on clinically relevant baseline characteristics. From both the Mayo Clinic and nationwide datasets, the observed coinfection rate for SARS-CoV-2 and influenza has been higher during the Omicron era (2021 December 14 to 2022 April 2) compared to previous waves, but no higher than expected assuming infection rates are independent. At the Mayo Clinic, only 120 coinfection cases were observed among 197,364 SARS-CoV-2 cases. Coinfected patients were relatively young (mean age: 26.7 years) and had fewer serious comorbidities compared to monoinfected patients. While there were no significant differences in 30-day hospitalization, ICU admission, or mortality rates between coinfected and matched COVID-19 monoinfection cases, coinfection cases reported higher rates of symptoms including congestion, cough, fever/chills, headache, myalgia/arthralgia, pharyngitis, and rhinitis. While most coinfection cases observed at the Mayo Clinic occurred among relatively healthy individuals, further observation is needed to assess outcomes among subpopulations with risk factors for severe COVID-19 such as older age, obesity, and immunocompromised status.
Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
Lomax-Browne, Hannah J. , Medjeral‐Thomas, Nicholas , Barbour, Sean J. , Gisby, Jack , Han, Heedeok , Fervenza, Fernando C. , Cairns, Thomas H D, Szydlo, Richard , Marks, Stephen D. , Waters, Aoife , Appel, Gerald B., D’Agati, Vivette D. , Sethi, Sanjeev , Nast, Cynthia C. , Bajema, Ingeborg M., Licht, Christoph , Cattran, Daniel C., Peters, James E. , Cook, H. Terence , Marks, Stephen D , Sethi, Sanjeev , Pickering, Matthew C , Fervenza, Fernando C , Bomback, Andrew S. , Tan, Sven‐Jean , Alpers, Charles E. , Fogo, Agnes B. , Fakhouri, Fádi

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 1, 2022 | Volume: 17 | Issue: 7 | Pages: 994-1007

10.2215/cjn.16801221 | PMID 35777834 Get It

Background and objectives C3 glomerulopathy and idiopathic Ig-associated membranoproliferative GN are kidney diseases characterized by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of patients develop kidney failure within 10 years. Design, setting, participants, & measurements To improve identification of patients with poor prognosis, we performed a detailed analysis of percutaneous kidney biopsies in a large cohort of patients. Using a validated histologic scoring system, we analyzed 156 native diagnostic kidney biopsies from a retrospective cohort of 123 patients with C3 glomerulopathy and 33 patients with Ig-associated membranoproliferative GN. We used linear regression, survival analysis, and Cox proportional hazards models to assess the relationship between histologic and clinical parameters with outcome. Results Frequent biopsy features were mesangial expansion and hypercellularity, glomerular basement membrane double contours, and endocapillary hypercellularity. Multivariable analysis showed negative associations between eGFR and crescents, interstitial inflammation, and interstitial fibrosis/tubular atrophy. Proteinuria positively associated with endocapillary hypercellularity and glomerular basement membrane double contours. Analysis of second native biopsies did not demonstrate associations between immunosuppression treatment and improvement in histology. Using a composite outcome, risk of progression to kidney failure associated with eGFR and proteinuria at the time of biopsy, cellular/fibrocellular crescents, segmental sclerosis, and interstitial fibrosis/tubular atrophy scores. Conclusions Our detailed assessment of kidney biopsy data indicated that cellular/fibrocellular crescents and interstitial fibrosis/tubular atrophy scores were significant determinants of deterioration in kidney function.
Exercise Testing in Heart Failure with Preserved Ejection Fraction: An Appraisal Through Diagnosis, Pathophysiology and Therapy – A Clinical Consensus Statement of the Heart Failure Association and European Association of Preventive Cardiology of the Europ
Wilhelm, Matthias , Craenenbroeck, Emeline M. Van , Boer, Rudolf A. de , Lund, Lars H. , Mancini, Donna , Filippatos, Gerasimos , Borlaug, Barry, de Boer, Rudolf A , Wilhelm, Matthias , Guazzi, Marco , Halle, Martin , Kemps, Hareld , Coats, Andrew J.S. , Borlaug, Barry A. , Pieske, Burkert

Mayo Clinic

European Journal of Heart Failure | July 1, 2022 | Volume: 24 | Issue: 8 | Pages: 1327-1345

10.1002/ejhf.2601 | PMID 35775383 Get It

Abstract Patients with heart failure with preserved ejection fraction (HFpEF) universally complain of exercise intolerance and dyspnoea as key clinical correlates. Cardiac as well as extracardiac components play a role for the limited exercise capacity, including an impaired cardiac and peripheral vascular reserve, a limitation in mechanical ventilation and/or gas exchange with reduced pulmonary vascular reserve, skeletal muscle dysfunction and iron deficiency/anaemia. Although most of these components can be differentiated and quantified through gas exchange analysis by cardiopulmonary exercise testing (CPET), the information provided by objective measures of exercise performance has not been systematically considered in the recent algorithms/scores for HFpEF diagnosis, by neither European nor US groups. The current clinical consensus statement by the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC) aims at outlining the role of exercise testing and its pathophysiological, clinical and prognostic insights, addressing the implications of a thorough functional evaluation from the diagnostic algorithm to the pathophysiology and treatment perspectives of HFpEF. Along with these goals, we provide a specific analysis of the evidence that CPET is the standard for assessing, quantifying, and differentiating the origin of dyspnoea and exercise impairment and even more so when combined with echocardiography and/or invasive haemodynamic evaluation. This will lead to improved quality of diagnosis when applying the proposed scores and may also help to implement the progressive characterization of the specific HFpEF phenotypes, a critical step toward the delivery of phenotype-specific treatments.
Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers
Weiner, Michael W. , Harvey, Danielle , Landau, Susan, Veitch, Dallas P. , Aisen, Paul, Petersen, Ronald C. , Tosun, Duygu , Shaw, Leslie M. , Trojanowski, John Q. , Saykin, Andrew J. , Carli, Charles De, DeCarli, Charles , Tosun, Duygu , DeCarli, Charles , Saykin, Andrew J , Harvey, Danielle J , Tosun, Duygu , Neylan, Thomas C. , Grafman, Jordan Henry , Jack, Clifford R. , Hayes, Jacqueline

Mayo Clinic

Alzheimer's & Dementia | June 29, 2022 | Volume: 19 | Issue: 3 | Pages: 884-895

10.1002/alz.12712 | PMID 35768339 Get It

AbstractIntroductionEpidemiological studies report an association between traumatic brain injury (TBI) and post‐traumatic stress disorder (PTSD) and clinically diagnosed Alzheimer's disease (AD). We examined the association between TBI/PTSD and biomarker‐defined AD.MethodsWe identified 289 non‐demented veterans with TBI and/or PTSD and controls who underwent clinical evaluation, cerebrospinal fluid (CSF) collection, magnetic resonance imaging (MRI), amyloid beta (Aβ) and tau positron emission tomography, and apolipoprotein E testing. Participants were followed for up to 5.2 years.ResultsExposure groups (TBI, PTSD, and TBI + PTSD) had higher prevalence of mild cognitive impairment (MCI: P < .0001) and worse Mini‐Mental State Examination scores (PTSD: P = .008; TBI & PTSD: P = .009) than controls. There were no significant differences in other cognitive scores, MRI volumes, Aβ or tau accumulation, or in most longitudinal measures.DiscussionTBI and/or PTSD were not associated with elevated AD biomarkers. The poorer cognitive status of exposed veterans may be due to other comorbid pathologies.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, Daniel A. , Hasserjian, Robert P. , Borowitz, Michael J., Kvasnicka, Hans Michael , Wang, Sa A. , Bagg, Adam , Barbui, Tiziano , Branford, Susan , Bueso‐Ramos, Carlos E. , Cortes, Jörge E. , Cin, Paola Dal , Dombret, Hervé , Duncavage, Eric J., Ebert, Benjamin L. , Estey, Elihu H. , Foucar, Kathryn , Gangat, Naseema , Gökbuget, Nicola , Hellström‐Lindberg, Eva , Beau, Michelle M. Le , Löwenberg, Bob , Malcovati, Luca , Odenike, Olatoyosi , Papaemmanuil, Elli , Porkka, Kimmo , Radich, Jerald P. , Reiter, Andreas , Rudelius, Martina , Schiffer, Charles A. , Sierra, Jorge , Stone, Richard M. , Tallman, Martin S. , Thiele, Jürgen, Tzankov, Alexandar , Wei, Andrew H. , Weinberg, Olga K. , Wierzbowska, Agnieszka , Cazzola, Mario , Tefferi, Ayalew , Hasserjian, Robert P , Kvasnicka, Hans-Michael , Barbui, Tiziano , Branford, Susan , Cortes, Jorge , DiNardo, Courtney , Ebert, Benjamin L , Gangat, Naseema , Gianelli, Umberto , Hobbs, Gabriela S , Larson, Richard A , Löwenberg, Bob , Macintyre, Elizabeth , Malcovati, Luca , Mullighan, Charles G , Niemeyer, Charlotte Marie , Ogawa, Seishi , Passamonti, Francesco , Porkka, Kimmo , Savona, Michael R , Schmitt-Graeff, Annette , Shimamura, Akiko , Vannucchi, Alessandro M , Vyas, Paresh , Wei, Andrew H , Wierzbowska, Agnieszka , Cazzola, Mario , Döhner, Hartmut , Tzankov, Alexandar , Arber, Daniel A , Orazi, Attilio , Calvo, Katherine R. , DiNardo, Courtney D. , Facchetti, Fabio , Gianelli, Umberto , Godley, Lucy A. , Gotlib, Jason , Hobbs, Gabriela , Hoffman, Ronald , Jabbour, Elias , Kiladjian, Jean‐Jacques , Larson, Richard A. , Loh, Mignon L. , Macintyre, Elizabeth , Mullighan, Charles G. , Órfão, Alberto , Passamonti, Francesco , Pui, Ching-Hon , Rozman, Marı́a , Savona, Michael R. , Stock, Wendy , Tien, Hwei‐Fang , Vannucchi, Alessandro M.

Mayo Clinic

Blood | June 29, 2022 | Volume: 140 | Issue: 11 | Pages: 1200-1228

10.1182/blood.2022015850 | PMID 35767897 Get It

Abstract The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
Vomer‐Rostrum Mucosal Flap for Exposed Bone Coverage After Sphenoid Sinusotomy
Goates, Andrew J. , Pinheiro‐Neto, Carlos , Choby, Garret , Pinheiro-Neto, Carlos D , Choby, Garret

Mayo Clinic

The Laryngoscope | June 29, 2022 | Volume: 133 | Issue: 3 | Pages: 552-556

10.1002/lary.30268 | PMID 35766378 Get It

Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review
Suri, Jasjit S. , Maindarkar, Mahesh , Paul, Sudip , Ahluwalia, Puneet , Bhagawati, Mrinalini , Saba, Luca , Faa, Gavino , Saxena, Sanjay , Singh, Inder M. , Chadha, Paramjit S., Turk, Monika, Johri, Amer M. , Khanna, Narendra N. , Višković, Klaudija , Mavrogeni, Sophie , Laird, John R. , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanase D. , Misra, Durga Prasanna , Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Sockalingam, Meyypan, Saxena, Ajit Kumar , Rathore, Vijay , Fatemi, Mostafa , Krishnan, Padukode R., Omerzu, Tomaž , Naidu, Subbaram, Paraskevas, Kosmas I. , Ruzsa, Zoltán , Fouda, Mostafa M. , Maindarkar, Mahesh A , Mavrogeni, Sophie , Sobel, David W , Tsoulfas, George , Fatemi, Mostafa , Naidu, Subbaram , Paraskevas, Kosmas I , Ruzsa, Zoltan , Fouda, Mostafa M , Misra, Durga Prasanna , Agarwal, Vikas , Protogerou, Athanasios , Faa, Gavino , Paul, Sudip , Bhagawati, Mrinalini , Suri, Jasjit S. , Saba, Luca , Kitas, George D. , Kolluri, Raghu , Sharma, Aditya , Alizad, Azra , Nicolaides, Andrew , Kalra, Mannudeep K.

Mayo Clinic

Diagnostics | June 25, 2022 | Volume: 12 | Issue: 7 | Pages: 1543

10.3390/diagnostics12071543 | PMID 35885449 Get It

Background and Motivation: Parkinson’s disease (PD) is one of the most serious, non-curable, and expensive to treat. Recently, machine learning (ML) has shown to be able to predict cardiovascular/stroke risk in PD patients. The presence of COVID-19 causes the ML systems to become severely non-linear and poses challenges in cardiovascular/stroke risk stratification. Further, due to comorbidity, sample size constraints, and poor scientific and clinical validation techniques, there have been no well-explained ML paradigms. Deep neural networks are powerful learning machines that generalize non-linear conditions. This study presents a novel investigation of deep learning (DL) solutions for CVD/stroke risk prediction in PD patients affected by the COVID-19 framework. Method: The PRISMA search strategy was used for the selection of 292 studies closely associated with the effect of PD on CVD risk in the COVID-19 framework. We study the hypothesis that PD in the presence of COVID-19 can cause more harm to the heart and brain than in non-COVID-19 conditions. COVID-19 lung damage severity can be used as a covariate during DL training model designs. We, therefore, propose a DL model for the estimation of, (i) COVID-19 lesions in computed tomography (CT) scans and (ii) combining the covariates of PD, COVID-19 lesions, office and laboratory arterial atherosclerotic image-based biomarkers, and medicine usage for the PD patients for the design of DL point-based models for CVD/stroke risk stratification. Results: We validated the feasibility of CVD/stroke risk stratification in PD patients in the presence of a COVID-19 environment and this was also verified. DL architectures like long short-term memory (LSTM), and recurrent neural network (RNN) were studied for CVD/stroke risk stratification showing powerful designs. Lastly, we examined the artificial intelligence bias and provided recommendations for early detection of CVD/stroke in PD patients in the presence of COVID-19. Conclusion: The DL is a very powerful tool for predicting CVD/stroke risk in PD patients affected by COVID-19.
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components
Snyder, Edward L. , Wheeler, Allison P. , Refaai, Majed A. , Cohn, Claudia S. , Poisson, Jessica , Fontaine, Magali J. , Sehl, Mary E. , Uhl, Lynne , Spinella, Philip C. , Fenelus, Maly , Coyle, Thomas, Becker, Joanne , Jeng, Michael , Spencer, Bryan R. , Young, Pampee P. , OʼBrien, Jennifer , Schiller, Gary J. , Roback, John D. , Malynn, Elizabeth, Jackups, Ronald , Avecilla, Scott T. , Lin, Jin‐Sying, Bentow, Stanley, Peng, Ho‐Lan, Varrone, Jeanne, Fontaine, Magali , Spinella, Philip C , Gehrie, Eric A , Spencer, Bryan R , Young, Pampee , O'Brien, Jennifer J, Avecilla, Scott T , Benjamin, Richard J , Corash, Laurence M , Cohn, Claudia S , Wheeler, Allison P , Jeng, Michael , Nooka, Ajay K. , Liles, Darla , Johnson, Andrew, Liu, Kathy

Mayo Clinic

Transfusion | June 24, 2022 | Volume: 62 | Issue: 7 | Pages: 1365-1376

10.1111/trf.16987 | PMID 35748490 Get It

AbstractBackgroundPlatelet transfusion carries risk of transfusion‐transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion‐related acute lung injury and acute respiratory distress syndrome (ARDS) occur with platelet transfusion.Study designAn open label, sequential cohort study of transfusion‐dependent hematology‐oncology patients was conducted to compare pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the incidence of treatment‐emergent assisted mechanical ventilation (TEAMV) by non‐inferiority. Secondary outcomes included: time to TEAMV, ARDS, pulmonary AEs, peri‐transfusion AE, hemorrhagic AE, transfusion reactions (TRs), PC and red blood cell (RBC) use, and mortality.ResultsBy modified intent‐to‐treat (mITT), 1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts had similar demographics, primary disease, and primary therapy. PRPC were non‐inferior to CPC for TEAMV (treatment difference −1.7%, 95% CI: (−3.3% to −0.1%); odds ratio = 0.53, 95% CI: (0.30, 0.94). The cumulative incidence of TEAMV for PRPC (2.9%) was significantly less than CPC (4.6%, p = .039). The incidence of ARDS was less, but not significantly different, for PRPC (1.0% vs. 1.8%, p = .151; odds ratio = 0.57, 95% CI: (0.27, 1.18). AE, pulmonary AE, and mortality were not different between cohorts. TRs were similar for PRPC and CPC (8.3% vs. 9.7%, p = .256); and allergic TR were significantly less with PRPC (p = .006). PC and RBC use were not increased with PRPC.DiscussionPRPC demonstrated reduced TEAMV with no excess treatment‐related pulmonary morbidity.
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
Bennani, N. Nora , Pederson, Levi , Atherton, Pamela J. , Micallef, Ivana N. , Thanarajasingam, Gita , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Bennani, N Nora , Kim, Hyo Jin , Witzig, Thomas E. , Feldman, Andrew L.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 24, 2022 | Volume: 10 | Issue: 6 | Pages: e004984

10.1136/jitc-2022-004984 | PMID 35750419 Get It

Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin’s lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade targeting program death receptor 1 would be effective in PTCL, we conducted an investigator-initiated phase 2 prospective study of single-agent nivolumab for RR PTCL. We report here results of the pre-specified interim analysis. Methods The primary objective was to assess the overall response rate (ORR). Secondary objectives were to assess safety and tolerability of nivolumab in PTCL and to assess progression-free survival (PFS), duration of response (DOR) and overall survival (OS). Hyperprogressive disease (HPD) was defined as time-to-treatment failure of less than or equal to one month from initiation of therapy. Results Twelve patients who received at least one cycle of nivolumab were included in this interim analysis. Half (6/12) of the patients had angioimmunoblastic T-cell lymphoma (AITL), 3/12 had PTCL, not otherwise specified. Most (11/12) were advanced stage, had extranodal disease (97.1%) and had received a prior autologous stem cell transplant (50%). The ORR was 33% (95% CI: 12.3 to 63.7%) with two complete response and two partial response. The median PFS was however short at 2.7 months (95% CI: 1.5 to NE); and the median OS was 6.7 months (95% CI: 3.4 to NE). The median DOR was also short at 3.6 months (95% CI: 1.9 to NE). HPD occurred in four patients, three of whom had AITL. Observed grade 3 and higher adverse events (AEs) were non-hematologic in 5/12 (42%), while hematologic AEs were seen in 3/12 (25%). Conclusions Nivolumab had modest clinical activity in R/R PTCL. Due to a high number of hyperprogression and short DOR, a decision was made to halt the study. These findings likely reflect the distinct biology of PTCL and should be considered when designing future studies using checkpoint inhibitors in these diseases. Trial registration number NCT03075553.